Relative Bioavailability of Intended Commercial Formulations (iCF) of BI 730357 Versus BI 730357 Trial Formulation 1 and Bioavailability Comparison of Three Different iCF Batches Following Oral Administration in Healthy Subjects (an Open-label, Single-dose, Randomised, 2-way and 3-way Crossover Trial)
Latest Information Update: 19 Jul 2023
At a glance
- Drugs BI 730357 (Primary)
- Indications Plaque psoriasis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 24 Jun 2019 Status changed from active, no longer recruiting to completed.
- 20 Jun 2019 Planned End Date changed from 18 Jun 2019 to 21 Jun 2019.
- 20 Jun 2019 Planned primary completion date changed from 18 Jun 2019 to 21 Jun 2019.